Oruka Therapeutics (ORKA) COO Laura Sandler Sells 906 Shares

What Happened Laura Sandler, Chief Operating Officer of Oruka Therapeutics, sold 906 shares on 2026-09-15 at $95.71 per share, generating proceeds of approximately $86,713. The filing shows this was a sale (transaction code S), and the sale was effected as a sell-to-cover related to the vesting of restricted stock units (RSUs), which is generally a routine tax-withholding action rather than a discretionary open-market divestiture.

Key Details

• Transaction date: 2026-09-15
• Price per share: $95.71; Shares sold: 906; Total proceeds: ~$86,713
• Transaction type: Sale (S) — reported as a sell-to-cover for tax withholding (see footnote F1)
• Footnote: Reported sales were effected pursuant to Oruka’s automatic, non-discretionary sell-to-cover procedure to satisfy tax withholding on RSU vesting (F1).
• Shares owned after transaction: Not disclosed in this filing.
• Filing timeliness: Reported on the same day (filed 2026-09-15), indicating a timely Form 4.

Context A sell-to-cover is an automatic transaction that companies commonly use to cover tax withholding when RSUs vest; it does not necessarily indicate the insider is reducing their overall stake by choice. For retail investors, purchases typically carry more weight as a bullish signal; routine sell-to-cover transactions are administrative and should be interpreted accordingly.